KMDA · Kamada Ltd
Market Cap
$457.07M
Shares
57.71M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.92
Open$8.05
Day$7.90–8.11
52W close$6.60–9.31
Avg vol 30d160K
Short int157K · 0.3% float · 1.0d
Short vol43%
Last earningsAug 12, 2026
DataJan 2020–Sep 2026
Up next
Next earnings call
Dec 17, 2026
Est · unconfirmed
· in 14 wks
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$180.46M
Trailing 12 months
Net income (TTM)
$20.44M
Trailing 12 months
Revenue growth YoY
+14.5%
Year over year
Operating margin
14.5%
Trailing 12 months
P / E (TTM)
22.6
Trailing earnings · reciprocal yield 4.4%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
5.3%
Trailing 12 months
Shares change YoY
+0.3%
Year over year · more shares
Price change (1Y)
+12.8%
Trailing year
Short interest
0.3%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Moderate
Market backdrop
VIX 15.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+1%
above
Price vs 50-day avg
+5%
above
RSI (14)
49
neutral
MACD trend
Negative
52-week position
49%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+9%
trailing
6-month return
−7%
trailing
YTD return
+12%
this year
Relative strength
−25%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $8 — 200d above 50d
Institutional flow
Accumulating
+19% holders QoQ · +12 funds added
Insider flow
Distributing
Net -$1.5M over 90 days · 100% sells
Short interest
Rising
0.27% of float · ▲ +4.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
51 holders — near 3-yr high, broad support
Squeeze score
36
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
34%
annualized · 1-yr
Max drawdown
−26%
past year
ATR
3.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
2026 annual
Revenues
Initiated
$200M – $205M
Adjusted EBITDA
Non-GAAP
Initiated
$50M – $53M
within the next four to five years
Biosimilars annual sales
$15M – $20M
at full capacity (per Houston and San Antonio facilities)
Annual revenues of sales of normal source plasma
$8M – $10M
Prior guidance
period ended
· from the Earnings Call filed Dec 31, 2021
Revenue
· 2022
$125M – $135M
EBITDA margins
· 2022
12% – 15%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+1%
Bullish
Price vs 50-day avg
+5%
Bullish
RSI (14)
49
Neutral
MACD trend
Negative
Bearish
52-week position
49%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $8 › 200d $8 — 200d above 50d
Institutional flow
Accumulating
+19% holders QoQ · +12 funds added
Insider flow
Distributing
Net -$1.5M over 90 days · 100% sells
Short interest
Rising
0.27% of float · ▲ +4.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
51 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $7
Now $8 · 49%
Range high $9
vs 200-day avg +1%
vs 50-day avg +5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KMDA
this stock
Kamada Ltd
|
$457.07M | +12.2% | — | — | 0.3% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$58.31B | +17.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$44.03B | -8.9% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$43.22B | +18.8% | +4.3% | 60.8 | 3.2% |
|
HLN
Haleon plc
|
$40.41B | -9.1% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KMDA | -4.2% | +9.1% | -6.8% | -3.8% | +12.2% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -3.1% | +10.8% | -24.7% | -3.4% | +0.1% |
Capital returns
Latest dividend
$0.17
/ share · ex Aug 27, 2026
Paid (TTM)
$0.42
/ share · 2 payouts
Dividend yield (TTM, derived)
— · history filling in
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1567529
CUSIP
M6240T109
13F (30d)
16 filings
16 filers
Visit website
Investor relations